CorMedix shares are trading higher after JMP Securities maintained an Outperform rate on the stock and raised its price target from $16 to $19.
Portfolio Pulse from Benzinga Newsdesk
CorMedix shares are trading higher after JMP Securities maintained an Outperform rating on the stock and raised its price target from $16 to $19.
May 19, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities maintained an Outperform rating on CorMedix and raised its price target from $16 to $19, leading to higher trading.
The news directly mentions CorMedix (CRMD) and states that JMP Securities has maintained an Outperform rating on the stock while raising its price target from $16 to $19. This positive analyst rating and increased price target are likely to have a short-term positive impact on the stock price, as it indicates increased confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100